FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036384609> ?p ?o ?g. }

• W3036384609 abstract "Abstract Background Recent approvals of second-generation androgen receptor inhibitors (SGARIs) have changed the treatment landscape for non-metastatic castration-resistant prostate cancer (nmCRPC). These SGARIs have similar efficacy but differ in safety profiles. We used a discrete choice experiment to explore how United States physicians make treatment decisions between adverse events (AEs) and survival gains in nmCRPC, a largely asymptomatic disease. Methods Treating physicians ( n = 149) participated in an online survey that included 14 treatment choice questions, each comparing 2 hypothetical treatment profiles, which varied in terms of 5 safety and 2 efficacy attributes. We described safety attributes (fatigue, skin rash, cognitive problems, falls, and fractures) in terms of severity and frequency, and efficacy attributes (overall survival [OS] and time to pain progression) in terms of duration of effect. We used a random parameters logit model to estimate preference weights and importance scores for each attribute. We also estimated the amount of survival gain physicians were willing to trade for a reduction in specific AEs between treatment options. Results Physicians placed more importance on survival than on time to pain progression, and viewed a reduction in cognitive problems from severe to none, a reduction in risk of a serious fracture from 8% to none, and a reduction in fatigue from severe to none as the most important safety attributes. Physicians were willing to forego 9.1 and 6.6 months of OS, respectively, to reduce cognitive problems and fatigue from severe to mild-to-moderate. To reduce the risk of a serious fracture from 8 to 5% and 5% to none, physicians were willing to trade 3.9 and 5.3 months of OS, respectively. Conclusions Physicians were willing to trade substantial amounts of survival to avoid AEs between hypothetical treatments. These results emphasize the importance of carefully balancing therapies’ benefits and risks to ultimately optimize the overall quality of nmCRPC patients’ survival. Nonetheless, it is noted that the results from the study sample of 149 physicans may not be representative of the viewpoints of all nmCRPC-treating physicians." @default.
• W3036384609 created "2020-06-25" @default.
• W3036384609 creator A5009847136 @default.
• W3036384609 creator A5022424470 @default.
• W3036384609 creator A5036735904 @default.
• W3036384609 creator A5044132384 @default.
• W3036384609 creator A5068725802 @default.
• W3036384609 creator A5073591312 @default.
• W3036384609 creator A5085500530 @default.
• W3036384609 creator A5087184017 @default.
• W3036384609 creator A5087836779 @default.
• W3036384609 date "2020-06-22" @default.
• W3036384609 modified "2023-10-16" @default.
• W3036384609 title "Physician preferences for non-metastatic castration-resistant prostate cancer treatment" @default.
• W3036384609 cites W1933249960 @default.
• W3036384609 cites W1968007670 @default.
• W3036384609 cites W1968486838 @default.
• W3036384609 cites W2032869670 @default.
• W3036384609 cites W2049553611 @default.
• W3036384609 cites W2065142831 @default.
• W3036384609 cites W2075459864 @default.
• W3036384609 cites W2094422835 @default.
• W3036384609 cites W2102015862 @default.
• W3036384609 cites W2102966185 @default.
• W3036384609 cites W2118709942 @default.
• W3036384609 cites W2121619367 @default.
• W3036384609 cites W2122503009 @default.
• W3036384609 cites W2132971882 @default.
• W3036384609 cites W2150402649 @default.
• W3036384609 cites W2154104453 @default.
• W3036384609 cites W2159936838 @default.
• W3036384609 cites W2296253991 @default.
• W3036384609 cites W2367707061 @default.
• W3036384609 cites W2506589396 @default.
• W3036384609 cites W2547875670 @default.
• W3036384609 cites W2602989120 @default.
• W3036384609 cites W2743350540 @default.
• W3036384609 cites W2792086148 @default.
• W3036384609 cites W2810806599 @default.
• W3036384609 cites W2885698302 @default.
• W3036384609 cites W2910205558 @default.
• W3036384609 cites W2913767564 @default.
• W3036384609 doi "https://doi.org/10.1186/s12894-020-00631-4" @default.
• W3036384609 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7310549" @default.
• W3036384609 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32571276" @default.
• W3036384609 hasPublicationYear "2020" @default.
• W3036384609 type Work @default.
• W3036384609 sameAs 3036384609 @default.
• W3036384609 citedByCount "8" @default.
• W3036384609 countsByYear W30363846092020 @default.
• W3036384609 countsByYear W30363846092021 @default.
• W3036384609 countsByYear W30363846092022 @default.
• W3036384609 countsByYear W30363846092023 @default.
• W3036384609 crossrefType "journal-article" @default.
• W3036384609 hasAuthorship W3036384609A5009847136 @default.
• W3036384609 hasAuthorship W3036384609A5022424470 @default.
• W3036384609 hasAuthorship W3036384609A5036735904 @default.
• W3036384609 hasAuthorship W3036384609A5044132384 @default.
• W3036384609 hasAuthorship W3036384609A5068725802 @default.
• W3036384609 hasAuthorship W3036384609A5073591312 @default.
• W3036384609 hasAuthorship W3036384609A5085500530 @default.
• W3036384609 hasAuthorship W3036384609A5087184017 @default.
• W3036384609 hasAuthorship W3036384609A5087836779 @default.
• W3036384609 hasBestOaLocation W30363846091 @default.
• W3036384609 hasConcept C118552586 @default.
• W3036384609 hasConcept C121608353 @default.
• W3036384609 hasConcept C126322002 @default.
• W3036384609 hasConcept C143998085 @default.
• W3036384609 hasConcept C151956035 @default.
• W3036384609 hasConcept C169900460 @default.
• W3036384609 hasConcept C194828623 @default.
• W3036384609 hasConcept C197934379 @default.
• W3036384609 hasConcept C2777910003 @default.
• W3036384609 hasConcept C2779134260 @default.
• W3036384609 hasConcept C2780192828 @default.
• W3036384609 hasConcept C71924100 @default.
• W3036384609 hasConcept C95057490 @default.
• W3036384609 hasConceptScore W3036384609C118552586 @default.
• W3036384609 hasConceptScore W3036384609C121608353 @default.
• W3036384609 hasConceptScore W3036384609C126322002 @default.
• W3036384609 hasConceptScore W3036384609C143998085 @default.
• W3036384609 hasConceptScore W3036384609C151956035 @default.
• W3036384609 hasConceptScore W3036384609C169900460 @default.
• W3036384609 hasConceptScore W3036384609C194828623 @default.
• W3036384609 hasConceptScore W3036384609C197934379 @default.
• W3036384609 hasConceptScore W3036384609C2777910003 @default.
• W3036384609 hasConceptScore W3036384609C2779134260 @default.
• W3036384609 hasConceptScore W3036384609C2780192828 @default.
• W3036384609 hasConceptScore W3036384609C71924100 @default.
• W3036384609 hasConceptScore W3036384609C95057490 @default.
• W3036384609 hasIssue "1" @default.
• W3036384609 hasLocation W30363846091 @default.
• W3036384609 hasLocation W30363846092 @default.
• W3036384609 hasLocation W30363846093 @default.
• W3036384609 hasLocation W30363846094 @default.
• W3036384609 hasOpenAccess W3036384609 @default.
• W3036384609 hasPrimaryLocation W30363846091 @default.
• W3036384609 hasRelatedWork W2049776456 @default.
• W3036384609 hasRelatedWork W2095199425 @default.
• W3036384609 hasRelatedWork W2097753790 @default.

• next